Company Overview
About Cerevance
Cerevance is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Cambridge, Massachusetts, focused on developing novel therapeutics for central nervous system (CNS) diseases. The company's core technological advantage is its NETSseq (Nuclear Enrichment for Transcriptome Sequencing) platform, which profiles gene expression at the individual cell-type level in post-mortem human brain tissue. By identifying transcriptional and epigenetic differences between specific cell types — such as dopaminergic neurons versus medium spiny neurons — Cerevance can discover drug targets that are active in disease-relevant cell populations and largely silent in others, enabling greater target selectivity and potentially better tolerability than broad CNS agents.
Business Model & Competitive Advantage
Cerevance's lead clinical program is CVN424, a highly selective GPR6 inverse agonist developed for Parkinson's disease. GPR6 is selectively expressed in striatal medium spiny neurons — making it an attractive target for improving motor function in Parkinson's with a reduced risk of the side effects associated with dopaminergic drugs. CVN424 completed a Phase 2 clinical trial evaluating its ability to reduce off-time in Parkinson's patients as an adjunct to levodopa. Cerevance has raised over $100M in total funding from investors including Johnson & Johnson Innovation (JJDC), GV (Google Ventures), Lilly Asia Ventures, and Morningside Venture Capital.
Competitive Landscape 2025–2026
The CNS drug discovery landscape is notoriously challenging, with high clinical failure rates driven by poor target validation and inadequate understanding of disease biology in human tissue. Cerevance's NETSseq platform directly addresses this by grounding target selection in human brain biology rather than animal models — a strategy that aligns with the broader industry shift toward human genetics and tissue-based target validation approaches being pursued by companies like Maze Therapeutics and Alector.
Key Differentiators
Emerging Innovator
Cerevance is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Cerevance with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Cerevance? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Cerevance Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Cerevance vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →